Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears IND application for phase II study of VB-111 in surgically accessible rGBM

Nov. 7, 2019

CD205-targeting antibody-drug conjugate shows selective antitumor efficacy in preclinical studies

Nov. 7, 2019

AGTC announces second ophthalmology program, reports promising preclinical data on dual AAV

Nov. 7, 2019

Measles vaccine far more protective than realized

Nov. 7, 2019

Low-coverage genome sequencing gives answers in infertility

Nov. 7, 2019

BerGenBio reports updated phase II data on bemcentinib in advanced NSCLC

Nov. 6, 2019

Dystrogen reports cardioprotective effects of DEC cells in Duchenne muscular dystrophy

Nov. 6, 2019

4D reports preliminary phase I/II data on MRx-0518 with pembrolizumab in advanced malignancies

Nov. 6, 2019

Shenzhen Targetrx Biotechnology patent details new tyrosine kinase inhibitors

Nov. 6, 2019

ATM and DNA-PK kinase inhibitors revealed in XRad Therapeutics patent

Nov. 6, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...